Monoclonal gammopathy and serum immunoglobulin levels as prognostic factors in chronic lymphocytic leukaemia.
Adult
Aged
Aged, 80 and over
Chromosome Deletion
Chromosomes, Human, Pair 12
Chromosomes, Human, Pair 17
/ genetics
Disease-Free Survival
Female
Follow-Up Studies
Humans
Immunoglobulin G
/ blood
Immunoglobulin M
/ blood
Leukemia, Lymphocytic, Chronic, B-Cell
/ blood
Male
Middle Aged
Neoplasm Proteins
/ blood
Paraproteinemias
/ blood
Retrospective Studies
Smith-Magenis Syndrome
/ blood
Survival Rate
Trisomy
Tumor Suppressor Protein p53
/ genetics
chronic lymphocytic leukemia
gamma globulin
monoclonal gammopathy
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
05
04
2020
accepted:
31
05
2020
pubmed:
28
7
2020
medline:
10
3
2021
entrez:
27
7
2020
Statut:
ppublish
Résumé
The relationship between chronic lymphocytic leukaemia (CLL) and qualitative/quantitative gammaglobulin abnormalities is well established. Nevertheless, in order to better understand this kind of connection, we examined 1505 patients with CLL and divided them into four subgroups on the basis of immunoglobulin (Ig) aberrations at diagnosis. A total of 73 (4·8%), 149 (10%), 200 (13·2%) and 1083 (72%) patients were identified with IgM monoclonal gammopathy (IgM/CLL), IgG monoclonal gammopathy (IgG/CLL), hypogammaglobulinaemia (hypo-γ) and normal Ig levels (γ-normal) respectively. IgM paraprotein was significantly associated with a more advanced Binet/Rai stage and del(17p)/TP53 mutation, while IgG abnormalities correlated with a higher occurrence of trisomy 12. Patients with any type of Ig abnormality had shorter treatment-free survival (TFS) but no significant impact affecting overall survival (OS) compared to those with normal Ig levels.
Substances chimiques
Immunoglobulin G
0
Immunoglobulin M
0
Neoplasm Proteins
0
TP53 protein, human
0
Tumor Suppressor Protein p53
0
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
901-908Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 British Society for Haematology and John Wiley & Sons Ltd.
Références
Caligaris-Cappio F, Hamblin TJ. B-cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol. 1999;17:399-408.
Shanafelt T. Treatment of older patients with chronic lymphocytic leukemia: key questions and current answers. Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 158-167.
Dighiero G, Binet JL. When and how to treat chronic lymphocytic leukemia. N Engl J Med. 2000;343:1799-801.
Caligaris-Cappio F, Ghia P. Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease? J Clin Oncol. 2008;26(27):4497-503.
Van Bockstaele F, Verhasselt B, Philippé J. Prognostic markers in chronic lymphocytic leukemia: a comprehensive review. Blood Rev. 2009;23:25-47.
Cole ME, MacFarlane A, Jillab M, Smith MR, Cohen AD, Campbell K. Immune cell dysfunction in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Blood. 2012; 120(21): 3875.
Tsai H-T, Caporaso NE, Kyle RA, Katzmann JA, Dispenzieri A, Hayes RB, et al. Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study. Blood. 2009;114:24.
Morrison VA. Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches. Best Pract Res Clin Haematol. 2010;23(1):145-53.
Ishdorj G, Streu E, Lambert P, et al. IgA levels at diagnosis predict for infections, time to treatment, and survival in chronic lymphocytic leukemia. Blood Adv. 2019;3(14):2188-98.
Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. Blood. 2015;126(5):573-81.
Atilla E, Atilla PA, Civriz Bozdag S, Kocak Toprak S, Topcuoglu P, Ilhan O, et al. does hypogammaglobulinemia at diagnosis effects survival and infection risk in chronic lymphocytic leukemia (CLL)? Blood. 2016;128(22):5577.
Foa R, Catovsky D, Brozovic M, Marsh G, Ooyirilangkumaran T, Cherchi M, et al. Clinical staging and immunological findings in chronic lymphocytic leukemia. Cancer. 1979;44(2):483-7.
Svensson T, Höglund M, Cherif H. Clinical significance of serum immunoglobulin G subclass deficiency in patients with chronic lymphocytic leukemia. Scand J Infect Dis. 2013;45(7):537-42.
Rozman C, Montserrat E, Viñolas N. Serum immunoglobulins in B-chronic lymphocytic leukemia. Natural history and prognostic significance. Cancer. 1988;61(2):279-83.
Andersen MA, Vojdeman FJ, Andersen MK, Brown Pde N, Geisler CH, Weis Bjerrum O, et al. Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia is a predictor of early death. Leuk Lymphoma. 2016;57(7):1592-9.
Colovic N, Bogdanovic A, Martinovic-Cemerikic V, Jankovic G. Prognostic significance of serum immunoglobulins in B-chronic lymphocytic leukemia. Arch Oncol. 2001;9:79-82.
Matutes E, Oscier D, Garcia-Marco J, Ellis J, Copplestone A, Gillingham R, et al. Trisomy 12 defines a group of CLL with atypical morphology: correlation between cytogenetic, clinical and laboratory features in 544 patients. Br J Haematol. 1996;92:382-8.
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446-56.
Hallek, M, Cheson, BD, Catovsky, D, Caligaris-Cappio, F, Dighiero, G, Döhner, H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131:2745-60.
Protein electrophoresis and immunofixation amitava dasgupta PhD, DABCC, Amer Wahed MD, in clinical chemistry, immunology and laboratory quality control, 2014: 391-7.
Reda G, Cassin R, Fattizzo B, Giannarelli D, Mattiello V, Barcellini W, et al. Chronic lymphocytic leukemia and prognostic models: a bridge between clinical and biological markers. Am J Hematol. 2017;92(7):E135-E137.
Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848-54.
Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910-6.
Crassini KR, Zhang E, Balendran S, Freeman JA, Best OG, Forsyth CJ, et al. Humoral immune failure defined by immunoglobulin class and immunoglobulin G subclass deficiency is associated with shorter treatment-free and overall survival in Chronic Lymphocytic Leukaemia. Br J Haematol. 2018;181:97-101.
Falisi E, Novella E, Visco C, Guercini N, Maura F, Giaretta I, et al. B-cell receptor configuration and mutational analysis of patients with chronic lymphocytic leukaemia and trisomy 12 reveal recurrent molecular abnormalities. Hematol Oncol. 2014;32(1):22-30.
Noel P, Kyle RA. Monoclonal proteins in chronic lymphocytic leukemia. Am J Clin Pathol. 1987;87(3):385-8.
Beaume A, Brizard A, Dreyfus B, Preud'homme JL. High incidence of serum monoclonal Igs detected by a sensitive immunoblotting technique in B-cell chronic lymphocytic leukemia. Blood. 1994;84(4):1216-9.
Bernstein ZP, Fitzpatrick JE, O'Donnell A, Han T, Foon KA, Bhargava A. Clinical significance of monoclonal proteins in chronic lymphocytic leukemia. Leukemia. 1992;6(12):1243-5.
Yang S, Zou ZJ, Li YY, Zhang L, Han T, Fanet L, et al. Prognostic significance of serum immunoglobulin paraprotein in chronic lymphocytic leukemia. Zhonghua Xue Ye Xue Za Zhi. 2012;33(10):795-800.
Alan C, Aisenberg MD, Bloch KJ, John C, Long MD. Cell-surface immunoglobulins in chronic lymphocytic leukemia and allied disorders. Am J Med. 1973;55(2):184-91.
Ten Hacken E, Sivina M, Kim E, O'Brien S, Wierda WG, Ferrajoli A, et al. Functional differences between IgM and IgD signaling in chronic lymphocytic leukemia. J Immunol. 2016;197(6):2522-31.
Efremov DG, Ivanovski M, Batista FD, Pozzato G, Burrone OR. IgM-producing chronic lymphocytic leukemia cells undergo immunoglobulin isotype-switching without acquiring somatic mutations. J Clin Invest. 1996;98(2):290-8.
Fais F, Sellars B, Ghiotto F, Yan XJ, Dono M, Allen SL, et al. Examples of in vivo isotype class switching in IgM+ chronic lymphocytic leukemia B cells. J Clin Invest. 1996;98(7):1659-66.
Reda G, Cassin R, Gentile M, Mauro FR, Giannarelli D, Fattizzo B, et al. IgA hypogammaglobulinemia predicts outcome in chronic lymphocytic leukemia. Leukemia. 2019;33:1519-22.
Yin CC, Lin P, Carney DA, Handy BC, Rassidakis GZ, Admirand JH, et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma associated with IgM paraprotein. Am J Clin Pathol. 2005;123(4):594-602.
Rizzo D, Chauzeix J, Trimoreau F, Woillard FB, Genevieve F, Bouvier A, et al. IgM peak independently predicts treatment-free survival in chronic lymphocytic leukemia and correlates with accumulation of adverse oncogenetic events. Leukemia. 2015;29:337-45.
Wadhwa PD, Morrison VA. Infectious complications of chronic lymphocytic leukemia. Semin Oncol. 2006;33(2):240-9.
Visentin A, Imbergamo S, Gurrieri C, Frezzato F, Trimarco V, Martini V, et al. Major infections, secondary cancers and autoimmune diseases occur in different clinical subsets of chronic lymphocytic leukaemia patients. Eur J Cancer. 2017;72:103-11.
Hamblin AD, Hamblin TJ. The immunodeficiency of chronic lymphocytic leukaemia. Br Med Bull. 2008;87:49-62.
Compagno N, Malipiero G, Cinetto F, Agostini C. Immunoglobulin replacement therapy in secondary hypogammaglobulinemia. Front Immunol. 2014;5:626.
Visentin A, Compagno N, Cinetto F, Imbergamo S, Zambello R, Piazza F, et al. Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy. Haematologica. 2015;100(12):e515-e518.
Matutes E, Polliack A. A matter of life or early death in CLL: do serum immunoglobulin levels really count? Leuk Lymphoma. 2016;57:1501-2.
Shvidel L, Tadmor T, Braester A, Bairey O, Rahimi-Levene N, Herishanu Y, et al. Israeli CLL Study Group. Serum immunoglobulin levels at diagnosis have no prognostic significance in stage A chronic lymphocytic leukemia: a study of 1113 cases from the Israeli CLL Study Group. Eur J Haematol. 2014;93(1):29-33.
Xu W, Wang Y, Fan L, Fang C, Zhu D, Wang D, et al. Prognostic significance of serum immunoglobulin paraprotein in patients with chronic lymphocytic leukemia. Leuk Res. 2011;35(8):1060-5.
Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94(6):1840-7.
Chauzeix J, Laforêt MP, Deveza M, Crowther L, Marcellaud E, Derouault P, et al. Normal serum protein electrophoresis and mutated IGHV genes detect very slowly evolving chronic lymphocytic leukemia patients. Cancer Med. 2018;7(6):2621-8.
Marinelli M, Ilari C, Xia Y, Del Giudice I, Cafforio L, Della Starza I, et al. Immunoglobulin gene rearrangements in Chinese and Italian patients with chronic lymphocytic leukemia. Oncotarget. 2016;7(15):20520-31.
Dighiero G, Travade P, Chevret S, Fenaux P, Chastang C, Binet JL. B-cell chronic lymphocytic leukemia: present status and future directions. French Cooperative Group on CLL. Blood. 1991;78:1901-14.
Sutton LA, Rosenquist R. Deciphering the molecular landscape in chronic lymphocytic leukemia: time frame of disease evolution. Haematologica. 2015;100(1), 7-16.